OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00053455

Wedge Industrial Co Ltd

PharmaceuticalsVerified

Wedge Industrial Co Ltd has a debt-to-equity ratio of 1.18, indicating a moderate level of leverage, and a current ratio of 1.06, suggesting limited short-term liquidity cushion. The company's free cash flow is negative at -270.0 million CNY, and capital expenditures are substantial at -430.4 million CNY, reflecting ongoing investment in long-term assets. The company's liquidity position is assessed as medium risk, with net cash negative after subtracting total debt. In terms of profitability, the company's return on equity is 12.29%, and return on assets is 4.29%, both of which are key metrics for evaluating performance in the pharmaceutical industry. These figures suggest that the company is generating reasonable returns relative to its equity and asset base, though the exact comparison to industry medians is not available in the provided data. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher operational and market risks if its primary market experiences downturns. The company's growth trajectory is not explicitly outlined in the available data, but its capital expenditures and free cash flow suggest a focus on long-term investment. The absence of forward-looking guidance in the provided data limits the ability to assess near-term revenue growth expectations. The company's risk profile includes a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key liquidity flag. No dilution sources are identified in the available data, and the dilution risk is assessed as low. Recent financial filings and transcripts are not provided in the available data, so no specific recent events can be cited. The company's financial snapshot is based on the latest available data from market data.

30-day price · 000534+0.01 (+0.0%)
Low$35.47High$46.60Close$35.76As of22 May, 00:00 UTC
Profile
CompanyWedge Industrial Co Ltd
Ticker000534.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Wedge Industrial Co Ltd is a pharmaceutical company that generates revenue primarily through the development and sale of pharmaceutical products.

Classification. Wedge Industrial Co Ltd is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a classification confidence of 0.92.

Wedge Industrial Co Ltd has a debt-to-equity ratio of 1.18, indicating a moderate level of leverage, and a current ratio of 1.06, suggesting limited short-term liquidity cushion. The company's free cash flow is negative at -270.0 million CNY, and capital expenditures are substantial at -430.4 million CNY, reflecting ongoing investment in long-term assets. The company's liquidity position is assessed as medium risk, with net cash negative after subtracting total debt. In terms of profitability, the company's return on equity is 12.29%, and return on assets is 4.29%, both of which are key metrics for evaluating performance in the pharmaceutical industry. These figures suggest that the company is generating reasonable returns relative to its equity and asset base, though the exact comparison to industry medians is not available in the provided data. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher operational and market risks if its primary market experiences downturns. The company's growth trajectory is not explicitly outlined in the available data, but its capital expenditures and free cash flow suggest a focus on long-term investment. The absence of forward-looking guidance in the provided data limits the ability to assess near-term revenue growth expectations. The company's risk profile includes a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key liquidity flag. No dilution sources are identified in the available data, and the dilution risk is assessed as low. Recent financial filings and transcripts are not provided in the available data, so no specific recent events can be cited. The company's financial snapshot is based on the latest available data from market data.
Key takeaways
  • Wedge Industrial Co Ltd has a moderate debt load with a debt-to-equity ratio of 1.18.
  • The company's return on equity of 12.29% indicates strong profitability relative to its equity base.
  • Free cash flow is negative, and capital expenditures are high, suggesting ongoing investment in long-term assets.
  • The company's liquidity position is assessed as medium risk due to a negative net cash position after subtracting total debt.
  • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.29B
Gross profit$913.9M
Operating income$199.1M
Net income$197.0M
R&D
SG&A
D&A
SBC
Operating cash flow$113.3M
CapEx-$430.4M
Free cash flow-$270.0M
Total assets$4.59B
Total liabilities$2.99B
Total equity$1.60B
Cash & equivalents
Long-term debt$1.90B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$1.29B$199.1M$197.0M-$270.0M
FY-1$1.08B$223.4M$192.7M-$431.2M
FY-2$981.4M$244.0M$176.6M-$190.5M
FY-3$793.8M$134.6M$101.7M-$229.6M
FY-4$656.3M$119.2M$95.3M-$129.8M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$4.59B$1.60B
FY-1$3.97B$1.36B$121.7k
FY-2$3.12B$1.21B
FY-3$2.43B$1.19B
FY-4$2.12B$1.07B
PeriodOCFCapExFCFSBC
FY0$113.3M-$430.4M-$270.0M
FY-1$114.3M-$586.8M-$431.2M
FY-2$94.7M-$390.7M-$190.5M
FY-3$194.9M-$341.6M-$229.6M
FY-4$136.7M-$216.7M-$129.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$359.8M$85.2M$77.5M
FQ-1$349.9M$12.4M$27.1M
FQ-2$315.2M$62.1M$50.5M
FQ-3$290.4M$37.9M$46.7M
FQ-4$335.0M$86.7M$72.7M
FQ-5$301.5M$48.3M$54.0M
FQ-6$274.6M$53.9M$40.8M
FQ-7$212.3M$44.8M$32.2M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$5.38B$1.72B$849.9M
FQ-1$4.59B$1.60B
FQ-2$4.35B$1.57B$239.6M
FQ-3$4.13B$1.50B$1.1M
FQ-4$4.08B$1.49B$264.4M
FQ-5$3.97B$1.36B$121.7k
FQ-6$3.57B$1.24B$190.4M
FQ-7$3.33B$1.15B
PeriodOCFCapExFCFSBC
FQ0-$26.8M-$172.7M
FQ-1$113.3M-$430.4M
FQ-2$16.6M-$418.4M
FQ-3$6.2M-$293.2M
FQ-4-$24.0M-$202.8M
FQ-5$114.3M-$586.8M
FQ-6$51.1M-$473.9M
FQ-7$2.8M-$306.8M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.60B
Net cash-$1.90B
Current ratio1.1
Debt/Equity1.2
ROA4.3%
ROE12.3%
Cash conversion57.0%
CapEx/Revenue-33.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric000534Activity
Op margin15.4%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin15.3%14.7% medp25 11.7% · p75 28.1%above median
Gross margin70.8%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-33.4%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity118.0%71.3% medp25 19.0% · p75 91.7%top quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-17 02:43 UTCJob: 4e39a1f4